Home/Filings/4/0001493152-24-018284
4//SEC Filing

Jones Mitchell Lawrence 4

Accession 0001493152-24-018284

CIK 0001357459other

Filed

May 7, 8:00 PM ET

Accepted

May 8, 6:37 PM ET

Size

15.8 KB

Accession

0001493152-24-018284

Insider Transaction Report

Form 4
Period: 2024-05-06
Jones Mitchell Lawrence
Chief Medical Officer
Transactions
  • Tax Payment

    Common Stock, par value $0.01

    2024-05-06$8.46/sh90$761724 total
  • Exercise/Conversion

    Common Stock, par value $0.01

    2024-05-06+156880 total
  • Exercise/Conversion

    Restricted Stock Units

    2024-05-063042,735 total
    Common Stock (304 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2024-05-061561,555 total
    Common Stock (156 underlying)
  • Exercise/Conversion

    Common Stock, par value $0.01

    2024-05-06+304814 total
  • Tax Payment

    Common Stock, par value $0.01

    2024-05-06$8.46/sh47$398833 total
Footnotes (7)
  • [F1]Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on September 5, 2023.
  • [F2]Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 1.
  • [F3]Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023.
  • [F4]Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 3.
  • [F5]Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
  • [F6]This restricted stock unit was granted on September 5, 2023, and 304 restricted stock units subject to the award vested on May 6, 2024, and an additional 2,735 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting.
  • [F7]This restricted stock unit was granted on November 21, 2023, and 156 restricted stock units subject to the award vested on May 6, 2024, and an additional 1,555 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting.

Documents

1 file

Issuer

PALISADE BIO, INC.

CIK 0001357459

Entity typeother

Related Parties

1
  • filerCIK 0001993292

Filing Metadata

Form type
4
Filed
May 7, 8:00 PM ET
Accepted
May 8, 6:37 PM ET
Size
15.8 KB